Genetic Dystonias
5 sections · 25 min
Classification of Dystonia
Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements or postures. The 2013 consensus classification uses two axes: Axis I (clinical features) and Axis II (etiology). Clinical features include age of onset (infantile, childhood, adolescent, adult), body distribution (focal, segmental, multifocal, generalized, hemidystonia), temporal pattern (static/progressive, persistent/task-specific/action-induced/diurnal), and associated features (isolated vs. combined with other movement disorders).
Key Points
- Isolated dystonia: dystonic movements are the only motor feature; formerly 'primary dystonia' — caused by pure dystonia genes (TOR1A, THAP1, GNAL, ANO3)
- Combined dystonia: dystonia plus another movement disorder (myoclonus, parkinsonism) — DYT-SGCE (myoclonus-dystonia), NBIA disorders, Wilson disease, DRD
- Complex dystonia: dystonia plus other neurological or systemic features — structural brain lesions, metabolic/genetic syndromes
- Diurnal fluctuation (worse late in day, improved by sleep) and dramatic levodopa response are hallmarks of dopa-responsive dystonia — always trial levodopa before concluding a childhood-onset dystonia is 'idiopathic'
- DYT numbering system: over 30 DYT loci designated; note that not all have confirmed causative genes, and some represent the same condition; current nomenclature: DYT-[gene] (e.g., DYT-TOR1A)
✦ Check Your Understanding
Myoclonus-dystonia (DYT-SGCE) shows a parent-of-origin effect because SGCE is:
Select an answer to reveal the explanation
Dopa-Responsive Dystonia: The Must-Not-Miss Diagnosis
Dopa-responsive dystonia (DRD), most commonly caused by autosomal dominant variants in GCH1 (encoding GTP cyclohydrolase 1), is the single most important treatable genetic dystonia. It is caused by deficiency of tetrahydrobiopterin (BH4), the essential cofactor for aromatic amino acid hydroxylases including tyrosine hydroxylase — the rate-limiting enzyme in dopamine synthesis. The response to low-dose levodopa is dramatic, sustained, and without motor fluctuations — distinguishing it from Parkinson disease. DRD is underdiagnosed because its initial presentation can mimic cerebral palsy, spastic diplegia, or idiopathic dystonia.
Key Points
- GCH1 (14q22.1): autosomal dominant, ~30% overall penetrance with marked female predominance (~2–4:1, likely due to hormonal modulation of dopamine synthesis); male carriers less frequently affected; onset typically childhood with leg dystonia and gait abnormality
- Classic features: childhood-onset foot dystonia/gait abnormality + diurnal fluctuation (worse at end of day, dramatic improvement after sleep) + brisk or exaggerated deep tendon reflexes
- CSF neurotransmitters: low biopterin, low neopterin, low HVA (homovanillic acid — dopamine metabolite); can confirm diagnosis but response to L-dopa is more practical
- Levodopa trial: start at 1–2 mg/kg/day; dramatic, sustained response at very low doses (25–50 mg/day) is virtually diagnostic; no dyskinesia, no motor fluctuations distinguish from PD
- SPR gene (sepiapterin reductase): autosomal recessive DRD; often more severe with parkinsonism; elevated sepiapterin in CSF; requires both levodopa AND serotonin precursors (5-HTP) for full treatment. DRD and related neurotransmitter disorders are also covered in the [[iem|Inborn Errors of Metabolism]] module
✦ Check Your Understanding
A 10-year-old girl is referred for foot dystonia and an abnormal gait that her parents note is much worse in the evening and dramatically improved after a night's sleep. The most appropriate first intervention is:
Select an answer to reveal the explanation
Early-Onset Primary Generalized Dystonia: DYT-TOR1A and DYT-THAP1
DYT-TOR1A (previously DYT1) is the most common form of early-onset primary generalized dystonia, caused by a dominantly inherited 3-bp in-frame deletion (ΔE303) in TOR1A, encoding torsinA — an AAA+ ATPase located in the endoplasmic reticulum lumen. TOR1A has markedly reduced penetrance (~30–40%), meaning most carriers do not develop clinically significant dystonia. Onset is typically in a limb in childhood, with variable generalization.
Key Points
- TOR1A ΔE303: in-frame GAG deletion accounts for nearly all pathogenic TOR1A variants; found in ~16% of Ashkenazi Jewish individuals who develop early-onset dystonia — founder effect
- Penetrance: only ~30–40% of TOR1A ΔE deletion carriers develop dystonia; onset before age 26 in affected individuals; onset in a limb, may generalize but often remains segmental
- TorsinA function: involved in nuclear envelope integrity and LINC complex function; pathogenic mechanism involves impaired nuclear-cytoskeletal coupling in striatal neurons
- Deep brain stimulation (DBS) of the globus pallidus internus (GPi): most effective treatment for medically refractory TOR1A dystonia; 50–90% sustained improvement in young patients
- DYT-THAP1 (previously DYT6): AD with ~60% penetrance; onset often in cranial/cervical muscles or arm; adolescent onset common; less responsive to DBS than DYT-TOR1A; THAP1 encodes a transcription factor regulating TOR1A expression
✦ Check Your Understanding
An Ashkenazi Jewish teenager develops left-hand writer's cramp at age 12 that gradually spreads to involve the leg and trunk over two years. Levodopa trial shows no response. Brain MRI is normal. What is the most likely diagnosis?
Select an answer to reveal the explanation
Combined Dystonia Syndromes
Combined dystonias feature dystonia as a prominent component alongside other movement disorders or neurological findings. Myoclonus-dystonia, dystonia-parkinsonism syndromes, and neurodegeneration with brain iron accumulation (NBIA) disorders are the major categories. Recognizing the combined phenotype markedly narrows the genetic differential.
Key Points
- DYT-SGCE (myoclonus-dystonia, DYT11): AD, maternally imprinted (paternal expression only); myoclonus of arms/trunk + mild dystonia; alcohol-responsive myoclonus; psychiatric comorbidity (OCD, anxiety); DBS/GPi effective
- KMT2B-dystonia (DYT28): autosomal dominant; childhood-onset generalized dystonia beginning in lower limbs; prominent oromandibular involvement; excellent response to GPi-DBS (one of the best DBS responders)
- Neurodegeneration with brain iron accumulation (NBIA): PKAN (PANK2), PLAN (PLA2G6), BPAN (WDR45, X-linked dominant) — T2 hypointensity in globus pallidus ('eye of the tiger' in PKAN), retinal degeneration (PLAN), intellectual regression (BPAN)
- Wilson disease (ATP7B): critical to exclude in any child/young adult with dystonia + liver disease; ceruloplasmin, 24-h urine copper, slit-lamp exam for Kayser-Fleischer rings; fully treatable with copper chelation
- ADCY5-related dyskinesia: AD; paroxysmal hyperkinetic movements with dystonia; prominent nocturnal exacerbations; choreic and dystonic features overlap; often misdiagnosed as sleep disorder
✦ Check Your Understanding
A child with early-onset generalized dystonia starting in the lower limbs has prominent oromandibular involvement. GPi-DBS is being considered. Which gene, if mutated, predicts an especially favorable DBS outcome?
Select an answer to reveal the explanation
Diagnostic Workup and Treatment of Genetic Dystonia
The evaluation of a patient with childhood-onset dystonia requires systematic exclusion of treatable causes before accepting a primary genetic diagnosis. The approach is guided by phenotype (isolated vs. combined, focal vs. generalized), family history, and associated findings. Genetic testing strategy has shifted toward panel-based NGS, but targeted testing is appropriate when the clinical picture strongly suggests a specific diagnosis.
Medication Overview
| Category | Agents | Key Notes |
|---|---|---|
| Dopaminergic | Levodopa/Carbidopa (Sinemet) | MANDATORY trial in all childhood-onset dystonia; dramatic response = DRD |
| Anticholinergic | Trihexyphenidyl | Most effective oral agent for generalized dystonia; titrate slowly |
| GABA-ergic | Baclofen (oral or intrathecal), Clonazepam | ITB pump for mixed spasticity-dystonia |
| VMAT2 Inhibitors | Tetrabenazine, Deutetrabenazine | Deplete monoamines; no tardive risk; useful in hyperkinetic combined dystonias |
| Botulinum Toxin | BoNT-A injections | Standard of care for focal/segmental dystonia |
| Neuromodulation | GPi-DBS | Best for TOR1A (50–90% improvement), KMT2B (excellent), SGCE (good) |
Trihexyphenidyl Titration Protocol
| Week | Dose | Frequency |
|---|---|---|
| Week 1 | 0.05 mg/kg | BID |
| Week 2 | 0.05 mg/kg | TID |
| Week 3 | 0.1 mg/kg | TID |
| Week 4 | 0.15 mg/kg | TID |
| Week 5 | 0.2 mg/kg | TID |
| Week 6+ | 0.25 mg/kg (max 0.5 mg/kg) | TID |
Adverse effects: dry mouth, urinary retention, cognitive changes. Contraindication: narrow-angle glaucoma.
Sinemet (Carbidopa/Levodopa 25/100) Titration Protocol
| Week | AM | Midday | PM |
|---|---|---|---|
| Week 1 | ½ tab | — | — |
| Week 2 | ½ tab | — | ½ tab |
| Week 3 | ½ tab | ½ tab | ½ tab |
| Week 4 | 1 tab | ½ tab | ½ tab |
| Week 5 | 1 tab | 1 tab | ½ tab |
| Week 6+ | 1 tab | 1 tab | 1 tab |
DRD response expected within days to 2 weeks. Give last dose ≤1600. Separate from iron supplements by ≥2 hours.
Key Points
- Treatable causes to exclude first: Wilson disease (ceruloplasmin, copper, slit lamp), DRD (levodopa trial, CSF neurotransmitters), NPC (filipin, NPC1/2 sequencing), biotinidase deficiency (serum biotinidase), glutaric aciduria type 1 (urine organic acids)
- Brain MRI: normal in isolated primary dystonia; T2 signal in putamen (Wilson disease), eye of the tiger in PKAN, white matter changes (PLAN, BPAN), iron deposition on T2*/susceptibility-weighted imaging
- Genetic panel testing: genes to include: TOR1A, THAP1, SGCE, KMT2B, GCH1, SPR, GNAL, ANO3, ATP7B, PANK2, PLA2G6, WDR45, ADCY5, ATP1A3 — large panels now available
- Deep brain stimulation (GPi-DBS): most effective for TOR1A (DYT1), KMT2B, and DYT-SGCE dystonias; less effective for some other combined dystonias; timing matters — earlier surgery before fixed postures develops
- Pharmacological approaches by mechanism: dopaminergic (levodopa for DRD — dramatic response), anticholinergic (trihexyphenidyl — most effective oral for generalized), tetrabenazine/VMAT2 inhibitors (depletes dopamine — helpful in hyperkinetic combined dystonias), botulinum toxin (focal/segmental dystonia — standard of care for cervical dystonia)
✦ Check Your Understanding
A young adult with dystonia and liver disease is found to have Kayser-Fleischer rings on slit-lamp examination. Ceruloplasmin is low. The correct diagnosis and treatment are:
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.